In this issue of EMBO Molecular Medicine, Liu et al (2022) report the remarkable therapeutic potential of two IMPDH inhibitors, MPA and FF‐10501‐01 for MLL‐rearranged AML. Here, KMT2A is linked to acute myeloid leukemia.